Sclerosis News and Research

RSS

RNA modification plays a vital role in TDP-43-related neurodegeneration in ALS

Nearly 100% of cases of amyotrophic lateral sclerosis-the progressive, fatal neurodegenerative disease known as ALS or Lou Gherig's disease-involve the buildup of a protein called TDP-43.

28 Feb 2023

New center at UCLA focuses on the microbiome’s role in disease prevention

Among the most promising areas of scientific inquiry is the study of the human microbiome and its effect on health. To fuel more rapid progress in this field, Andrea and Donald Goodman and Renee and Meyer Luskin have made a $20 million gift to establish the UCLA Goodman–Luskin Microbiome Center.

16 Feb 2023

WashU researcher receives NIH grant to study a poorly understood protein linked to ALS

The relentless neurological disease amyotrophic lateral sclerosis (ALS) eventually shuts down the entire body, but the devastation starts at a molecular level.

14 Feb 2023

Large-scale differentiation of iPSC-derived motor neurons from ALS patients

A new Cedars-Sinai study in collaboration with the University of California, Irvine (UCI) and the Answer ALS consortium has examined the expression of thousands of genes in stem cell generated motor neurons that are known to die in patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig's disease.

10 Feb 2023

Differences in the gut microbiomes of people with ME/CFS revealed

Discrepancies in the gut microbiomes of people having myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) than those of healthy controls have been disclosed by newly performed research.

9 Feb 2023

Potential approach for mitigating ALS pathogenesis

Every year, 5,000 people in the United States are diagnosed with ALS, an incurable neurodegenerative disease that will destroy them within two to five years.

8 Feb 2023

Promotional spending share allocated to consumer advertising higher for drugs with low added benefit

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the share of promotional spending allocated to consumer advertising was on average 14.3 percentage points higher for drugs with low added benefit compared to drugs with high added benefit.

8 Feb 2023

RNA-G quadruplexes in living cells: A real-time study

Amyotrophic lateral sclerosis (ALS), sometimes referred to as Stephen Hawking’s disease and Lou Gehrig’s disease is a neurological condition that causes the body’s muscles to gradually lose control.

2 Feb 2023

Simple inexpensive test determines the genetic susceptibility to PML

Four genetic mutations have been linked to progressive multifocal leukoencephalopathy (PML), a rare but sometimes fatal brain infection that can be provoked by dozens of FDA-approved drugs.

16 Dec 2022

Scientist honored for his contribution on ALS research

The Drs Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing was given to Clive Svendsen, PhD, a pioneer in regenerative medicine, for his significant contributions to the field of amyotrophic lateral sclerosis (AL) at Massachusetts General Hospital’s Sean M. Healey & AMG Center for ALS.

12 Dec 2022

RNA-targeting strategy to repair the genetic cause of ALS and dementia

Researchers at UF Scripps Biomedical Research have created a potential treatment for a major factor in the development of ALS and dementia that functions by removing disease-causing RNA segments.

24 Nov 2022

Regeneration of the immune system in MS patients

Transplanting blood stem cells is a new but incredibly successful treatment for multiple sclerosis. Now, a study directed by the University of Zurich has looked closely at how the autoimmune disease is controlled by the treatment and how the immune system recovers afterward.

14 Nov 2022

Revitalized immune cells improve waste removal from the brain

Damaged protein clusters in the brain are a hallmark of many neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and others. Although they have made significant efforts, scientists have only partially succeeded in finding treatments for these conditions by removing these toxic clusters.

11 Nov 2022

Resistance against Epstein-Barr virus from experimental monoclonal antibodies

When tested in a lab setting using human cells, a panel of experimental monoclonal antibodies (mAbs) that target various Epstein-Barr virus (EBV) sites prevented infection.

1 Nov 2022

Drug discovery method facilitates promising treatment approaches for metabolic diseases

The body’s chemical processes known as “metabolism” produce the raw materials needed for development and general health.

17 Oct 2022

Brain-resident and recruited macrophages exhibit diverging responses

Prof. Kiavash Movahedi (VUB, VIB) headed a group that outlined how the immune system responds to infections entering the brain. The results offer new information on host-pathogen interactions as well as the long-term effects of brain infections.

14 Oct 2022

Researchers reveal key developmental difference between the brains of modern humans and Neanderthals

AZoLifesciences speaks to Dr. Anneline Pinson and Prof. Dr. Wieland B. Huttner from The Max Planck Institute of Molecular Cell Biology and Genetics about their latest research which found a greater neuron production in the frontal lobe during brain development in modern humans than Neanderthals, due to the change of a single amino acid in the protein TKTL1.

From The Max Planck Institute 20 Sep 2022